N/A N=133 Skin Health and Effectiveness of Standardized Skin Care Regimens in Nursing Home Residents
Xerosis Cutis
Primary: Change From Baseline in Overall Dry Skin Score (ODS) — -0.9; -1.2; -0.9 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=32 Development of Dermatology-related Quality of Life Assessment in Patients Treated With Epidermal Growth Factor Receptor (EGFR) Inhibitors
Skin Toxicities
Primary: Qualitative Data From Patients and Experts to Measure Anti-EGFR Therapy-specific Health-related Quality of Life (HRQL) — 2.70; 2.41; 2.70; 2.29 units on a scale
N/A N=465 The Impact of a Dermatology Information Source on Skin Problem Outcomes in Primary Care
Decision Support Systems,Clinical · Skin Diseases
Primary: Number of Patients With Resolved Skin Problems — 72; 135 Participants — p=0.54
N/A N=21 Psoriasis Inflammation and Systemic Co Morbidities
Psoriasis
Primary: Change in Histology
Phase 3 N=11 Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT
Cetuximab-induced Papulopustular (Acneiform) Rash Who Have · Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma
Primary: Number of Patients in Which the PI Observed a Notable Difference in the Number of Lesions — 4; 4 participants
Phase 4 N=24 Evaluating Treatment Resistant Dermatitis TaroIIR
Atopic Dermatitis · Psoriasis
Primary: Investigator Global Assessment- Atopic Dermatitis — 1.7; 1.5 units on a scale
Phase 3 N=162 Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer
Actinic Keratosis · Warts · Basal Cell Carcinoma
Primary: Number of Accumulated New Skin Lesions at Month 3 — 65; 103 new skin lesions — p=0.0120
N/A N=135 Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions
Drug Hypersensitivity
Primary: Skin Healing Time — 13.75; 19; 40.5; 34 days — p=0.01
Phase 4 N=90 Combination Therapy for Atopic Dermatitis
Atopic Dermatitis
Primary: Change From Baseline in the m-EASI (Eczema Area Severity Index) Score. — 5.04; 4.77 units of a 0-12 scale — p=<0.05
Phase 2 N=187 RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
Breast Cancer
Primary: Time-averaged Effect on Radiation Dermatitis Grade Measured With Common Terminology Criteria for Adverse Events (CTCAE, v 4.03) Following 3D Conformal Radiation Therapy…
Phase 2 N=95 Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy
Metastatic Colorectal Cancer · Skin Rash · Skin Toxicities
Primary: Percentage of Participants With Specific Grade 2 or Higher Skin Toxicities During the 6-week Skin Treatment Period — 29; 62 percentage of participants
Phase 3 N=537 Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers
Venous Leg Ulcer
Primary: Complete Healing of the Study Ulcer by Week 16. — 201; 176 participants — p=0.1030
Phase 2 N=30 Rosacea and Ivermectin
Rosacea
Primary: Adherence - MEMs Cap — 21; 6; 15; 12 Participants
Phase 2 N=1 5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts
Ectropion · Skin Neoplasms
Primary: Graft Size Change — 10 percent change in graft
Phase 4 N=15 Healing Ointment Usage Post-surgical Procedure
Surgical Wound
Primary: Objective Erythema Assessment Using Clinical Grading Analog Scale — 0.8; 0.83; 0.75; 0.29 score on a scale
Phase 4 N=528 CeraVe Diabetes Mellitus
Diabetes Complications
Primary: Percentage of Participants Reporting Adverse Events (AE) — 0 percentage of participants
Phase 2 N=20 Dakin's Solution in Preventing Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy
Breast Cancer · Skin Reactions Secondary to Radiation Therapy
Primary: Percent of Women Who Develop Grade 3 or 4 Radiation Dermatitis (as Defined by the Stanford Radiation Dermatitis Scoring System) During a Course of Radiation Therapy — 6…
Phase 2 N=42 Botulinum Toxin is a Potential Prophylactic Therapy for Minimizing Post-excisional Scarring (Allergan Botox Scar Study)
Post-operative Excessive Scarring
Primary: Modified Manchester Scar Scale (MMSS) Score — 8; 11.5 score on a scale
Phase 4 N=107 Decreasing Intraoperative Skin Damage in Prone Position Surgeries
Pressure Injury
Primary: Number of Participants With Intraoperative Acquired Pressure Injuries (IAPI) — 13; 14 Participants
Phase 2 N=175 Preventing Diabetic Foot Ulcers Through Cleaner Feet
Diabetic Foot Ulcer
Primary: Time to New Foot Complication Among All Randomized Participants — 12; 14 Participants
N/A N=74 Wet-to-dry vs Petrolatum & Non-stick Dressings After Hidradenitis Suppurativa Surgery
Hidradenitis Suppurativa · Surgical Wound
Primary: Wound QOL Survey Score Over Time — 1.14; 0.94; 0.77; 0.66 score on a scale
N/A N=60 Treatment of Staphylococcus Aureus Colonization in Hand Eczema
Hand Eczema · Foot Eczema
Primary: Number of Participants With PGA of 0 or 1 — 22; 14 participants — p=0.035
N/A N=32 Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors
Skin Rash
Primary: Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and…
N/A N=57 Radiotherapy Related Skin Toxicity: Mepitel® vs. Standard Care in Patients With Locally Advanced Head-and-Neck Cancer
Head and Neck Neoplasms
Primary: Number of Participants With Grade ≥2 Radiation Dermatitis at 50 Gy (Per Protocol Set) — 3; 9; 6; 18 Participants
N/A N=12 Comparing the Effects of Three Different Dressings on the Cutaneous Response of Sacral Skin
Pressure Ulcer Prevention
Primary: Change in Skin Surface Temperature From Baseline — 3.1; 3.8; 3.0; 3.3 °C
N/A N=11 Effect of Dermal Rejuvenation on the UVB Response of Geriatric Skin
Pre-cancerous Geriatric Skin
Primary: Difference in Basal Layer Keratinocytes Positive for Both Ki67 and Thymine Dimers — 21.5; 14.7 positive cells/1000 basal layer cells
N/A N=9 Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy
Atopic Dermatitis · Eczema
Primary: SCORAD Change Score — 33.34 Change Score
Phase 4 N=6 Can We Miss Pigmented Lesions in Psoriasis Patients?
Psoriasis · Melanoma · Non-melanoma Skin Cancer
Primary: The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques. — 0 participants
Phase 2 N=6 Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated Calcinosis
Calcinosis
Primary: Change in Dermatomyositis-associated Calcinosis of a Single Lesion by Assessing Its Severity as Measured by a Difference in Physician Calcinosis Visual Analog Scales…
N/A N=1,260 A Community-based Assessment of Skin Care, Allergies, and Eczema
Atopic Dermatitis · Atopic Disorders · Eczema
Primary: Provider-diagnosed Atopic Dermatitis — 217.7; 268.5 Participants with imputed values — p=0.019